Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Early Phase 1

2(25.0%)

Phase 2

2(25.0%)

8Total

Phase 1(4)

Early Phase 1(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06373380Early Phase 1Active Not Recruiting

A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)

Role: collaborator

NCT06430905Phase 1Terminated

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Role: lead

NCT04180215Phase 1Completed

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Role: lead

NCT04630353Early Phase 1Terminated

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

Role: lead

NCT06771674Completed

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Role: lead

NCT06513884Phase 2Withdrawn

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Role: lead

NCT05553639Phase 1Terminated

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Role: lead

NCT03629080Phase 2Completed

A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

Role: lead

NCT02798692Phase 1Completed

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

Role: lead

All 9 trials loaded